Drug Trial Radar · NCT03937479
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
Last checked: Nov 20, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
May 1, 2019
Primary completion
Nov 15, 2019
Study completion Nov 15, 2019
Sponsor
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd; LGC Limited
- First posted
- May 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.
Conditions
- COPD
Interventions
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropiumDrug
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropiumDrug
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropiumDrug
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropiumDrug
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropiumDrug
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4Time frame: Baseline and Week 4
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
California Research Medical Group, Inc
Fullerton, California
Southern California Institute For Respiratory Diseases, Inc.
Los Angeles, California
Innovative Clinical Research
Lafayette, Colorado
Meris Clinical Research
Brandon, Florida
Clinical Research of West Florida
Clearwater, Florida
Pulmonary Disease Specialists, PA d/b/a PDS Research
Kissimmee, Florida
Medical Research of Central Florida, LLC
Leesburg, Florida
Clinical Trials of Florida, LLC
Miami, Florida
Peninsula Research, Ormond Beach, LLC
Ormond Beach, Florida
Medsol Clinical Research Center, Inc
Port Charlotte, Florida
Progressive Medical Research
Port Orange, Florida
Pasadena Center for Medical Research, LLC
St. Petersburg, Florida
Florida Pulmonary Research Institute, LLC
Winter Park, Florida
Columbus Regional Research Institute
Columbus, Georgia
VitaLink Research - Hamilton Mill
Dacula, Georgia
VitaLink Research - Duluth
Duluth, Georgia
Gwinnett Biomedical Research
Lawrenceville, Georgia
IACT Health
Rincon, Georgia
Vitalink
Winder, Georgia
Genesis Clinical Research and Consulting, LLC
Fall River, Massachusetts
Pulmonary Research Institute of Southeast Michigan
Farmington Hills, Michigan
Cities Research Center
Fridley, Minnesota
American Health Research
Charlotte, North Carolina
Clinical Research of Gastonia
Gastonia, North Carolina
Research Carolina of Huntersville
Huntersville, North Carolina
Clinical Research of Lake Norman
Mooresville, North Carolina
New Horizons Clinical Research
Cincinnati, Ohio
Aventiv Research, Inc
Columbus, Ohio
Aventiv Research, Inc
Dublin, Ohio
Crisor, LLC
Medford, Oregon
Vitalink Research - Anderson
Anderson, South Carolina
Lowcountry Lung and Critical Care, PA
Charleston, South Carolina
VitaLink-Columbia
Columbia, South Carolina
VitaLink Research - Easley
Easley, South Carolina
Piedmont Research Partners, LLC
Fort Mill, South Carolina
VitaLink Research-Gaffney
Gaffney, South Carolina
VitaLink Research-Greenville
Greenville, South Carolina
VitaLink Research-UPSTATE
Greenville, South Carolina
Clinical Research of Charleston
Mt. Pleasant, South Carolina
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.